When Everyone Is Involved, Who Is Accountable?

Sarah Sink
Jan 29
3 min read

Most development programs do not struggle because teams lack expertise. They struggle because no one is quite sure who owns the decision when complexity shows up.

A method result trends unexpectedly.

A process parameter needs to change.

A fill/finish adjustment creates downstream questions.

Everyone is involved, but accountability becomes unclear.

In complex development and manufacturing programs, strong governance is not about control. It is about clarity. Without it, even well-designed programs can lose momentum.

Governance Is More Than Project Management

Governance is often mistaken for meeting cadence, status reports, or escalation paths. In reality, it defines how decisions are made, documented, and communicated across the lifecycle.

Effective governance spans:

Development and scale-up
Analytical strategy and comparability
Tech transfer and manufacturing
Sterile fill/finish and supply planning

When governance is clear, teams move forward with confidence. When it is not, programs slow down as decisions are revisited, reinterpreted, or deferred.

Where Governance Breaks Down

Governance issues tend to surface at transition points.

Common examples include:

Moving from development into GMP manufacturing
Transferring methods or processes to a CDMO
Preparing for sterile fill/finish for the first time
Scaling volumes or changing containers
Managing post-change impact on comparability

At these moments, multiple teams have valid input. Development, manufacturing, quality, analytics, and fill-finish SMEs all see risk from different angles.

Without clear decision ownership, teams debate instead of decide.

Why Sterile Fill/Finish Amplifies Governance Gaps

Sterile fill/finish often exposes governance weaknesses more than earlier stages.

Decisions around container closure systems, filtration strategies, hold times, line configuration, and aseptic controls carry significant downstream impact. Once fill/finish planning begins, timelines tighten and flexibility narrows.

If governance is unclear, teams hesitate to act or move forward without full alignment. That is when surprises surface late and confidence erodes.

Programs that integrate fill/finish into governance discussions early protect timelines, supply continuity, and trust across teams.

The Role of CDMO Partnerships

Governance does not stop at the sponsor organization. It extends into CDMO partnerships.

Strong CDMO partners do more than execute. They actively participate in governance by:

Raising risks early
Providing context alongside data
Aligning recommendations with program goals
Supporting timely, well-informed decisions

From a business development perspective, this is a critical differentiator. CDMOs that foster collaborative governance help programs move faster with fewer surprises.

This is not about shifting responsibility. It is about making informed decisions together.

What Strong Programs Do Differently

High-performing programs tend to share a few governance habits:

Decision ownership is clearly defined
SMEs are involved before changes are finalized
Rationale is documented, not just outcomes
Development, manufacturing, and fill finish are aligned
Escalation paths are understood and respected

These programs spend less time revisiting decisions and more time executing them.

Why Governance Matters to Business Development

For business development professionals, governance is one of the most important and least discussed success factors.

When BD understands how decisions are made and owned, they can help sponsors set realistic expectations and choose partners that support collaboration rather than confusion.

Clear governance builds trust. Trust accelerates execution.

Strong BD professionals do not just sell capability. They help structure partnerships that can withstand complexity.

Final Thoughts

Program success is not defined solely by science, capacity, or speed. It is defined by how well decisions are made when things change.

Governance provides the structure that allows expertise to be applied effectively across development, manufacturing, and sterile fill/finish.

If your team is evaluating CDMOs or comparing proposals, it is worth asking not only what a partner can do, but how decisions will be made when change inevitably occurs.

My guide, How to Compare CDMO Quotes: 10 Factors Beyond Cost, helps teams assess partners through a broader lens, including communication, ownership, and execution readiness across the full program lifecycle.

Because clarity is not a nice-to-have. It is a competitive advantage.

For more insights and personalized support in navigating the biotech-CDMO landscape, visit www.yourpharmagirl.com and follow Your Pharma Girl. Whether you need strategic guidance, tailored business development solutions, or expert advice on building lasting partnerships, I am here to help you and your team succeed at every stage of development.